Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2579

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2579
---
 some or none of such shares at
any time or from time to time in its sole discretion and at different prices.

We
are not required or permitted to issue any shares of common stock under the Common Stock Purchase Agreement if such issuance would breach
our obligations under the rules or regulations of Nasdaq. Further, White Lion will not be required to purchase any shares of our common
stock if such sale would result in White Lion’s beneficial ownership exceeding 9.99% of our outstanding shares of common stock.
Our inability to access a part or all of the amount available under the Common Stock Purchase Agreement, in the absence of any other
financing sources, could have a material adverse effect on our business.

The
sale and issuance of shares of common stock to White Lion will cause dilution to our existing securityholders, and the resale of the
shares of common stock by White Lion, or the perception that such resales may occur, could cause the price of our securities to fall.

The
purchase price per share of common stock to be paid by White Lion for the shares of common stock that we may elect to sell to White Lion
under the Common Stock Purchase Agreement, if any, will fluctuate based on the market prices of our shares of common stock at the time
we elect to sell shares of common stock to White Lion pursuant to the Common Stock Purchase Agreement. Depending on market liquidity
at the time, resales of such shares of common stock by White Lion may cause the trading price of our shares of common stock to fall.

If
and when we elect to sell shares of common stock to White Lion, sales of newly issued shares of common stock by us to White Lion could
result in substantial dilution to the interests of existing holders of our shares of common stock. Additionally, the sale of a substantial
number of shares of common stock to White Lion, or the anticipation of such sales, could make it more difficult for us to sell equity
or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

We
may use proceeds from sales of our common stock made pursuant to the Common Stock Purchase Agreement in ways with which you may not agree
or in ways which may not yield a significant return.

74

We
will have broad discretion over the use of proceeds from sales of our shares of common stock made pursuant to the Common Stock Purchase
Agreement and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being